Substituted aromatic compounds and pharmaceutical uses thereof
The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and/or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and/or (iv) oxidative stress related disorders.
1. An isolated compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein:
n is 1;
Q is C 1 -C 2 alkyl;
R 1 is straight chain C 5 alkyl, C 6 alkyl, C 5- C 6 alkenyl, or C 5 -C 6 alkynyl;
R 2 is H, halogen, haloalkyl, OR b , SR b , or NR c R d ;
R 3 is H, halogen, haloalkyl, straight chain C 1 -C 4 alkyl, OR b , SR b , or NR c R d ;
R 4 is H, halogen, haloalkyl, C 1 -C 4 alkyl, OR b , SR b , or NR c R d ;
R 5 is H or OR b ;
R b is H; and
R c and R d are independently chosen from: H or C 1 -C 4 alkyl.
2. A compound of claim 1 , wherein the pharmaceutically acceptable salt is a base addition salt, the base addition salt is a metal counterion, and the metal counterion is sodium, magnesium, calcium, potassium or lithium.
3. A compound of claim 2 , wherein the metal counterion is sodium.
4. A compound selected from the group consisting of:
5. The compound of claim 4 , wherein the compound is:
6. The compound of claim 4 , wherein the compound is:
7. The compound of claim 4 , wherein the compound is:
8. The compound of claim 4 , wherein the compound is:
9. The compound of claim 4 , wherein the compound is:
10. The compound of claim 4 , wherein the compound is:
11. The compound of claim 4 , wherein the compound is:
12. The compound of claim 4 , wherein the compound is:
13. The compound of claim 4 , wherein the compound is:
14. The compound of claim 4 , wherein the compound is:
15. The compound of claim 4 , wherein the compound is:
16. The compound of claim 4 , wherein the compound is:
17. The compound of claim 4 , wherein the compound is:
18. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition comprising a compound of claim 4 , and a pharmaceutically acceptable carrier.
20. A compound of claim 1 , wherein R 1 is straight chain C 5 alkyl, C 6 alkyl, or C 5- C 6 alkenyl; and R 2 is H, halogen, haloalkyl, or OR b .
21. A compound of claim 1 , wherein R 3 is independently chosen from: H, halogen, haloalkyl, straight chain C 1 -C 4 alkyl, or OR 6 ; and R 4 is independently chosen from: H, halogen, haloalkyl, C 1 -C 4 alkyl, or OR b .
22. An isolated pharmaceutically acceptable salt of a compound of Formula II
wherein:
n is 1;
Q is C 1 -C 2 alkyl;
R 1 is straight chain C 5 alkyl, C 6 alkyl, C 5 -C 6 alkenyl, or C 5 -C 6 alkynyl;
R 2 is H, halogen, haloalkyl, OR b , SR b , or NR C R d ;
R 3 is H, halogen, haloalkyl, straight chain C 1 -C 4 alkyl, OR b , SR b , or NR C R d ;
R 4 is H, halogen, haloalkyl, C 1 -C 4 alkyl, OR b , SR b , or NR C R d ;
R 5 is H or OR b ;
R b is H; and
R c and R d are independently chosen from: H or C 1 -C 4 alkyl,
wherein the pharmaceutically acceptable salt is a base addition salt, the base addition salt is a metal counterion, and the metal counterion is sodium, magnesium, calcium, potassium or lithium.
23. A pharmaceutical composition comprising an isolated compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein:
n is 1;
Q is C 1 -C 2 alkyl;
R 1 is straight chain C 5 alkyl, C 6 alkyl, C 5 -C 6 alkenyl, or C 5 -C 6 alkynyl;
R 2 is H, halogen, haloalkyl, OR b , SR b , or NR C R d ;
R 3 is H, halogen, haloalkyl, straight chain C 1 -C 4 alkyl, OR b , SR b , or NR C R d ;
R 4 is H, halogen, haloalkyl, C 1 -C 4 alkyl, OR b , SR b , or NR C R d ;
R 5 is H or OR b ;
R b is H; and
R c and R d are independently chosen from: H or C 1 -C 4 alkyl,
and a pharmaceutically acceptable carrier.